Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: A phase i clinical trial

Bone Marrow Transplantation

Volumn 49, Issue 8, 2014, Pages 1056-1062

  Herbert, K E ^a   Demosthenous, L ^a   Wiesner, G ^a   Link, E ^a   Westerman, D A ^a   Came, N ^a   Ritchie, D S ^a,b   Harrison, S ^a,b   Seymour, J F ^a,b   Prince, H M ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; HETEROCYCLIC COMPOUND; PEGFILGRASTIM; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; AGED; APHERESIS; ARTICLE; BONE PAIN; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FACIAL PARESTHESIA; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOMA; MALE; MULTIPLE MYELOMA; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RISK FACTOR; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; TUMOR CELL; AUTOGRAFT; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROCEDURES;

ADULT; ANTI-HIV AGENTS; AUTOGRAFTS; BLOOD COMPONENT REMOVAL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECOMBINANT PROTEINS;

EID: 84905711196     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.112     Document Type: Article

References (35)

1. Harousseau JL, Attal M, Divine M, Milpied N, Marit G, Leblond V et al. Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. Bone Marrow Transplant 1995; 15: 963-969.
2. To LB, Roberts MM, Haylock DN, Dyson PG, Branford AL, Thorp D et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277-284.
3. Koc ON, Gerson SL, Cooper BW, Laughlin M, Meyerson H, Kutteh L et al. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol 2000; 18: 1824-1830.
4. Demirer T, Buckner CD, Gooley T, Appelbaum FR, Rowley S, Chauncey T et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 937-941.
5. Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D, Fassas A et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998; 16: 1547-1553.
6. Rettig MP, Ramirez P, Nervi B, DiPersio JF. CXCR4 and mobilization of hematopoietic precursors. Methods Enzymol 2009; 460: 57-90.
7. Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201: 1307-1318.
8. Douglas S, Smith C, McFarland R, Badel K, Calandra G. AMD3100 with G-CSF for autologous peripheral blood progenitor cell (PBPC) mobilization in non-hodgkin's lymphoma (NHL) and multiple myeloma (MM): mobilization, engraftment, and pharmacokinetics (PK). Blood ASH Annual Meeting Abstracts 2006; 108: 3383.
9. Ehninger G, Fruehauf S, Hubel K, Platzbecker U, Badel K, Calandra G. Steady state mobilization of autologous blood stem cells using G-CSF and AMD3100 in patients with multiple myeloma (MM). Blood ASH Annual Meeting Abstracts 2006; 108: 5219.
10. Flomenberg N, Devine SM, DiPersio JF, Liesveld JL, McCarty JM, Rowley SD et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867-1874.
11. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-4773.
12. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-5726.
13. Gaugler B, Arbez J, Legouill S, Tiberghien P, Moreau P, Derenne S et al. Characterization of peripheral blood stem cell grafts mobilized by granulocyte colonystimulating factor and plerixafor compared with granulocyte colony-stimulating factor alone. Cytotherapy 2013; 15: 861-868.
14. Biganzoli L, Untch M, Skacel T, Pico JL. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin Oncol 2004; 31(3 Suppl 8): 27-34.
15. Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005; 35: 33-36.
16. Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP et al. A single dose of 6 or 12mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006; 46: 180-185.
17. Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P et al. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999; 27: 1724-1734.
18. Kroschinsky F, Holig K, Poppe-Thiede K, Zimmer K, Ordemann R, Blechschmidt M et al. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica 2005; 90: 1665-1671.
19. Hosing C, Qazilbash MH, Kebriaei P, Giralt S, Davis MS, Rhodes B et al. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilization in patients with multiple myeloma (MM). Blood ASH Annual Meeting Abstracts 2005; 106: 2923.
20. Herbert KE, Gambell P, Link EK, Mouminoglu A, Wall DM, Harrison SJ et al. Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells. Bone Marrow Transplant 2013; 48: 351-356.
21. Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008; 93: 431-438.
22. Russell N, Douglas K, Ho AD, Mohty M, Carlson K, Ossenkoppele GJ et al. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial. Haematologica 2013; 98: 172-178.
23. Mohty M, Duarte RF, Croockewit S, Hubel K, Kvalheim G, Russell N. The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia 2011; 25: 1-6.
24. Kroschinsky F, Holig K, Platzbecker U, Poppe-Thiede K, Ordemann R, Blechschmidt M et al. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma. Transfusion 2006; 46: 1417-1423.
25. Costa LJ, Miller AN, Alexander ET, Hogan KR, Shabbir M, Schaub C et al. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant 2011; 46: 523-528.
26. Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011; 46: 64-69.
27. Costa LJ, Kramer C, Hogan KR, Butcher CD, Littleton AL, Shoptaw KB et al. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion 2012; 52: 2375-2381.
28. Anwer F, Green M, Yeager AM. Effective primary mobilization of autologous peripheral blood stem cells with granulocyte colony-stimulating factor and plerixafor in lenalidomide-treated patients with multiple myeloma Blood 2010; 116 abstract 2254
29. Schulman KA, Birch R, Zhen B, Pania N, Weaver CH. Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheralblood stem-cell support. J Clin Oncol 1999; 17: 1227.
30. Grignani G PE, Cavalloni G, Carnevale Schianca F, Aglietta M. Letter to the Editor: clinical use of AMD3100 to mobilize CD34+ cells in patients affected by nonhodgkin's lymphoma or multiple myeloma. J Clin Oncol 2005; 23: 3871-3872.
31. Liesveld JL, Bechelli J, Rosell K, Lu C, Bridger G, Phillips G 2nd et al. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res 2007; 31: 1553-1563.
32. Nervi B, Holt M, Rettig MP, Bridger G, Ley TJ, DiPersio JF. AMD3100 mobilizes acute promyelocytic leukemia cells from the bone marrow into the peripheral blood and sensitizes leukemia cells to chemotherapy. Blood ASH Annual Meeting Abstracts 2005; 106: 246.
33. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK et al. Chemosensitization of AML following mobilization by the CXCR4 antagonist AMD3100. Blood 2009; 113: 6206-6214.
34. Tricot G, Cottler-Fox MH, Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant 2010; 45: 63-68.
35. Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2010; 46: 64-69